The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
TLR7 and TLR8 as targets in cancer therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
Nuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519 · cited 1×
“This phosphorylation results in release, activation and nuclear translocation of NF-kB, where it induces transcription of a multitude of genes, including those of cytokines, chemokines, adhesion molecules and apoptosisrelated proteins (Karin, 2006).”
BackgroundInnate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway
Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T., Tomizawa, H., Takeda, K., & Akira, S. (2002) · Nature Immunology · doi:10.1038/ni758 · Cited by 2,522
Recognition of single-stranded RNA viruses by Toll-like receptor 7
Lund, J. M., Alexopoulou, L., Sato, A., Karow, M., Adams, N. C., Gale, N. W., Iwasaki, A., & Flavell, R. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400937101 · Cited by 1,861
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., & MacLachlan, I. (2005) · Nature Biotechnology · doi:10.1038/nbt1081 · Cited by 1,250
Hornung, V., Guenthner-Biller, M., Bourquin, C., Ablasser, A., Schlee, M., Uematsu, S., Noronha, A., Manoharan, M., Akira, S., de Fougerolles, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1191 · Cited by 1,232
The evolution of vertebrate Toll-like receptors
Roach, J. C., Glusman, G., Rowen, L., Kaur, A., Purcell, M. K., Smith, K. D., Hood, L. E., & Aderem, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502272102 · Cited by 1,171
Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848
Jurk, M., Heil, F., Vollmer, J., Schetter, C., Krieg, A. M., Wagner, H., Lipford, G., & Bauer, S. (2002) · Nature Immunology · doi:10.1038/ni0602-499 · Cited by 838
Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8
Gorden, K. B., Gorski, K. S., Gibson, S. J., Kedl, R. M., Kieper, W. C., Qiu, X., Tomai, M. A., Alkan, S. S., & Vasilakos, J. P. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.3.1259 · Cited by 683
Lee, J., Chuang, T.-H., Redecke, V., She, L., Pitha, P. M., Carson, D. A., Raz, E., & Cottam, H. B. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0631696100 · Cited by 592
Heil, F., Ahmad‐Nejad, P., Hemmi, H., Hochrein, H., Ampenberger, F., Gellert, T., Dietrich, H., Lipford, G., Takeda, K., Akira, S., et al. (2003) · European Journal of Immunology · doi:10.1002/eji.200324238 · Cited by 518
Geisse, J., Caro, I., Lindholm, J., Golitz, L., Stampone, P., & Owens, M. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2003.11.066 · Cited by 505
Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential
Stanley, M. A. (2002) · Clinical and Experimental Dermatology · doi:10.1046/j.1365-2230.2002.01151.x · Cited by 377
Gibson, S. J., Lindh, J. M., Riter, T. R., Gleason, R. M., Rogers, L. M., Fuller, A. E., Oesterich, J. L., Gorden, K. B., Qiu, X., McKane, S. W., et al. (2002) · Cellular Immunology · doi:10.1016/s0008-8749(02)00517-8 · Cited by 375
Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells
Stary, G., Bangert, C., Tauber, M., Strohal, R., Kopp, T., & Stingl, G. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070021 · Cited by 363
Lebwohl, M., Dinehart, S., Whiting, D., Lee, P. K., Tawfik, N., Jorizzo, J., Lee, J. H., & Fox, T. L. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2003.12.010 · Cited by 293
Loré, K., Betts, M. R., Brenchley, J. M., Kuruppu, J., Khojasteh, S., Perfetto, S., Roederer, M., Seder, R. A., & Koup, R. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.8.4320 · Cited by 291
Suzuki, H., Wang, B., Shivji, G. M., Toto, P., Amerio, P., Sauder, D. N., Tomai, M. A., & Miller, R. L. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00833.x · Cited by 284
Wille-Reece, U., Flynn, B. J., Loré, K., Koup, R. A., Miles, A. P., Saul, A., Kedl, R. M., Mattapallil, J. J., Weiss, W. R., Roederer, M., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052433 · Cited by 275
New insights into the regulation of TLR signaling
Miggin, S. M., & O’Neill, L. A. J. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.1105672 · Cited by 267
Wagner, T. L., Ahonen, C. L., Couture, A. M., Gibson, S. J., Miller, R. L., Smith, R. M., Reiter, M. J., Vasilakos, J. P., & Tomai, M. A. (1999) · Cellular Immunology · doi:10.1006/cimm.1998.1406 · Cited by 258
Tumor-Selective Induction of Apoptosis and the Small-Molecule Immune Response Modifier Imiquimod
Schon, M., Bong, A. B., Drewniok, C., Herz, J., Geilen, C. C., Reifenberger, J., Benninghoff, B., Slade, H. B., Gollnick, H., & Schon, M. P. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg016 · Cited by 258
Schulze, H. J., Cribier, B., Requena, L., Reifenberger, J., Ferrandiz, C., Garcia Diez, A., Tebbs, V., & McRae, S. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06486.x · Cited by 244
Nishiya, T., & DeFranco, A. L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311618200 · Cited by 236
TLR3 and TLR7 Are Targeted to the Same Intracellular Compartments by Distinct Regulatory Elements
Nishiya, T., Kajita, E., Miwa, S., & DeFranco, A. L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504951200 · Cited by 217
Odashima, M., Bamias, G., Rivera-Nieves, J., Linden, J., Nast, C. C., Moskaluk, C. A., Marini, M., Sugawara, K., Kozaiwa, K., Otaka, M., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.05.032 · Cited by 205
Stockfleth, E. (2002) · Archives of Dermatology · doi:10.1001/archderm.138.11.1498 · Cited by 205
Prins, R. M., Craft, N., Bruhn, K. W., Khan-Farooqi, H., Koya, R. C., Stripecke, R., Miller, J. F., & Liau, L. M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.157 · Cited by 203
Gorden, K. K. B., Qiu, X. X., Binsfeld, C. C. A., Vasilakos, J. P., & Alkan, S. S. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.6584 · Cited by 203
Palamara, F., Meindl, S., Holcmann, M., Lührs, P., Stingl, G., & Sibilia, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.5.3051 · Cited by 201
Szeimies, R.-M., Gerritsen, M.-J. P., Gupta, G., Ortonne, J. P., Serresi, S., Bichel, J., Lee, J. H., Fox, T. L., & Alomar, A. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2004.02.022 · Cited by 193
Sterry, W., Ruzicka, T., Herrera, E., Takwale, A., Bichel, J., Andres, K., Ding, L., & Thissen, M. R. T. M. (2002) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2002.05069.x · Cited by 191
Imiquimod and resiquimod as novel immunomodulators
Dockrell, D. H. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.6.751 · Cited by 185
Urosevic, M., Dummer, R., Conrad, C., Beyeler, M., Laine, E., Burg, G., & Gilliet, M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji207 · Cited by 182
Imbertson, L. M., Couture, A. M., Gibson, S. J., Smith, R. M. A., Miller, R. L., Reiter, M. J., Wagner, T. L., Tomai, M. A., & Beaurline, J. M. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00174.x · Cited by 173
Opposing actions of STAT-1 and STAT-3
Stephanou, A., & Latchman, D. S. (2005) · Growth Factors · doi:10.1080/08977190500178745 · Cited by 173
Patel, G. K., Goodwin, R., Chawla, M., Laidler, P., Price, P. E., Finlay, A. Y., & Motley, R. J. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.01.055 · Cited by 172
Role of Toll‐like receptors in costimulating cytotoxic T cell responses
Schwarz, K., Storni, T., Manolova, V., Didierlaurent, A. M., Sirard, J., Röthlisberger, P., & Bachmann, M. F. (2003) · European Journal of Immunology · doi:10.1002/eji.200323919 · Cited by 171
Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine.
Sidky, Y. A., Borden, E. C., Weeks, C. E., et al. (1992) · PubMed · Cited by 169
Cytokine induction in mice by the immunomodulator imiquimod
Reiter, M. J., Tester man, T. L., Miller, R. L., Weeks, C. E., & Tomai, M. A. (1994) · Journal of Leukocyte Biology · doi:10.1002/jlb.55.2.234 · Cited by 168
Schön, M. P., Schön, M., & Klotz, K.-N. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700286 · Cited by 164
Self-citationCutting Edge: Priming of CTL by Transcutaneous Peptide Immunization with Imiquimod
Rechtsteiner, G., Warger, T., Osterloh, P., Schild, H., & Radsak, M. P. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.5.2476 · Cited by 164
Korman, N., Moy, R., Ling, M., Matheson, R., Smith, S., McKane, S., & Lee, J. H. (2005) · Archives of Dermatology · doi:10.1001/archderm.141.4.467 · Cited by 164
Imiquimod for Actinic Keratosis: Systematic Review and Meta-Analysis
Hadley, G., Derry, S., & Moore, R. A. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700264 · Cited by 162
Levy, O., Suter, E. E., Miller, R. L., & Wessels, M. R. (2006) · Blood · doi:10.1182/blood-2005-12-4821 · Cited by 161
Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists
Gorski, K. S., Waller, E. L., Bjornton-Severson, J., Hanten, J. A., Riter, C. L., Kieper, W. C., Gorden, K. B., Miller, J. S., Vasilakos, J. P., Tomai, M. A., et al. (2006) · International Immunology · doi:10.1093/intimm/dxl046 · Cited by 158
Harrison, C. J., Jenski, L. J., Voychehovski, T., & Bernstein, D. I. (1988) · Antiviral Research · doi:10.1016/0166-3542(88)90032-0 · Cited by 154
Bong, A. B., Bonnekoh, B., Franke, I., Schön, M. P., Ulrich, J., & Gollnick, H. P. M. (2002) · Dermatology · doi:10.1159/000063904 · Cited by 152
Self-citationTopical Imiquimod in the Treatment of Metastatic Melanoma to Skin
Wolf, I. H., Smolle, J., Binder, B., Cerroni, L., Richtig, E., & Kerl, H. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.3.273 · Cited by 147
Imiquimod 5 percent cream and the treatment of cutaneous malignancy
Navi, D., & Huntley, A. C. (2004) · Dermatology Online Journal · doi:10.5070/d34vw339w4 · Cited by 146
Interventions for basal cell carcinoma of the skin: systematic review
Bath-Hextall, F. J., Bong, J. L., Perkins, W. A., & Williams, H. C. (2004) · BMJ · doi:10.1136/bmj.38219.515266.ae · Cited by 145
Mechanisms Underlying Imiquimod-Induced Regression of Basal Cell Carcinoma In Vivo
Urosevic, M., Maier, T., Benninghoff, B., Slade, H. B., Burg, G., & Dummer, R. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.10.1325 · Cited by 145
Megyeri, K., Au, W.-C., ROSZTÓCZY, I., Raj, N. B. K., Miller, R. L., Tomai, M. A., & Pitha, P. M. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.4.2207 · Cited by 139
Schön, M. P., Wienrich, B. G., Drewniok, C., Bong, A. B., Eberle, J., Geilen, C. C., Gollnick, H. P. M., & Schön, M. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.22528.x · Cited by 138
Self-citationBurns, R. P., Ferbel, B., Tomai, M. A., Miller, R. L., & Gaspari, A. A. (2000) · Clinical Immunology · doi:10.1006/clim.1999.4804 · Cited by 129
The Immune Response Modifiers Imiquimod and R-848 Are Potent Activators of B Lymphocytes
Tomai, M. A., Imbertson, L. M., Stanczak, T. L., Tygrett, L. T., & Waldschmidt, T. J. (2000) · Cellular Immunology · doi:10.1006/cimm.2000.1673 · Cited by 126
Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases
Stockfleth, E., Meyer, T., Benninghoff, B., & Christophers, E. (2001) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2001.04197.x · Cited by 122
Shackleton, M. J., Davis, I. D., Hopkins, W., Jackson, H. M., Dimopoulos, N., Tai, T. Y., Chen, Q., Parente, P., Jefford, M., Masterman, K., et al. (2004) · PubMed · Cited by 122
Gerster, J. F., Lindstrom, K. J., Miller, R. L., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049211v · Cited by 119
Thomsen, L. L., Topley, P., Daly, M. G., et al. (2004) · Vaccine · doi:10.1016/j.vaccine.2003.09.052 · Cited by 109
Treatment of Lentigo Maligna (Melanoma In Situ) With the Immune Response Modifier Imiquimod
Wolf, I. H., Cerroni, L., Kodama, K., & Kerl, H. (2005) · Archives of Dermatology · doi:10.1001/archderm.141.4.510 · Cited by 106
Oligodeoxynucleotides Differentially Modulate Activation of TLR7 and TLR8 by Imidazoquinolines
Gorden, K. B., Qiu, X., Battiste, J. L., Wightman, P. D., Vasilakos, J. P., & Alkan, Ş. Ş. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.11.8164 · Cited by 103
Jurk, M., Kritzler, A., Schulte, B., Tluk, S., Schetter, C., Krieg, A. Μ., & Vollmer, J. (2006) · European Journal of Immunology · doi:10.1002/eji.200535806 · Cited by 101
Suchin, K. R. (2002) · Archives of Dermatology · doi:10.1001/archderm.138.9.1137 · Cited by 96
TLR8-mediated NF-κB and JNK Activation Are TAK1-independent and MEKK3-dependent
Qin, J., Yao, J., Cui, G., Xiao, H. Q., Kim, T. W., Frączek, J., Wightman, P. D., Sato, S., Akira, S., Puel, A., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512908200 · Cited by 95
Imiquimod-Induced Interleukin-1α Stimulation Improves Barrier Homeostasis in Aged Murine Epidermis
Barland, C. O., Zettersten, E., Brown, B. S., Ye, J., Elias, P. M., & Ghadially, R. (2004) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2004.22203.x · Cited by 88
Efficacy of S26308 against guinea pig cytomegalovirus infection
Chen, M., Griffith, B. P., Lucia, H. L., & Hsiung, G. D. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.5.678 · Cited by 84
Bernstein, D. I., Harrison, C. J., Tomai, M. A., & Miller, R. L. (2001) · The Journal of Infectious Diseases · doi:10.1086/319262 · Cited by 82
Berman, B., Sullivan, T. P., Araujo, T. D., & Nadji, M. (2003) · British Journal of Dermatology · doi:10.1046/j.0366-077x.2003.05634.x · Cited by 79
Imiquimod in basal cell carcinoma: how does it work?
Dummer, R., Urosevic, M., Kempf, W., Hoek, K. S., Hafner, J., & Burg, G. (2003) · British Journal of Dermatology · doi:10.1046/j.0366-077x.2003.05630.x · Cited by 78
Gollnick, H. P. M., Barona, C. G., Frank, R. G. J., Ruzicka, T., Megahed, M., Tebbs, V. M., Owens, M., & Stampone, P. A. (2005) · PubMed · Cited by 75
Sauder, D. N., Smith, M. H., Senta-McMillian, T., Soria, I., & Meng, T. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.12.3846-3852.2003 · Cited by 74
Topical Immunomodulation in Dermatology: Potential of Toll-like Receptor Agonists
Hengge, U. R., & Ruzicka, T. (2004) · Dermatologic Surgery · doi:10.1111/j.1524-4725.2004.30335.x · Cited by 73
The Immune Response Modifier Resiquimod Mimics CD40-Induced B Cell Activation
Bishop, G. A., Ramirez, L. M., Baccam, M., Busch, L. K., Pederson, L. K., & Tomai, M. A. (2001) · Cellular Immunology · doi:10.1006/cimm.2001.1769 · Cited by 68
Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis
Vidal, D., Matías‐Guiu, X., & Alomar, A. (2004) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2004.06094.x · Cited by 60
Hurwitz, D., Pincus, L. B., & Kupper, T. S. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.10.1347 · Cited by 59
Immunomodulation as a treatment strategy for genital herpes: review of the evidence
Miller, R. L., Tomai, M. A., Harrison, C. J., & Bernstein, D. I. (2002) · International Immunopharmacology · doi:10.1016/s1567-5769(01)00184-9 · Cited by 51
Inhibition of IgE Production by the Imidazoquinoline Resiquimod in Nonallergic and Allergic Donors
Frotscher, B., Anton, K., & Worm, M. (2002) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2002.19531.x · Cited by 41
Giannotti, B., Vanzi, L., Difonzo, E. M., & Pimpinelli, N. (2003) · Clinical and Experimental Dermatology · doi:10.1046/j.1365-2230.28.s1.11.x · Cited by 39
Bottrel, R. L. A., Yang, Y., Levy, D. E., Tomai, M. A., & Reis, L. F. L. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.4.856 · Cited by 37
The treatment of basal skin carcinomas in two sisters with xeroderma pigmentosum
Roseeuw, D. (2003) · Clinical and Experimental Dermatology · doi:10.1046/j.1365-2230.28.s1.10.x · Cited by 31
Cited by
Differential macrophage programming in the tumor microenvironment
Ruffell, B., Affara, N. I., & Coussens, L. M. (2012) · Trends in Immunology · doi:10.1016/j.it.2011.12.001 · Cited by 860
Interstitial leukocyte migration and immune function
Friedl, P., & Weigelin, B. (2008) · Nature Immunology · doi:10.1038/ni.f.212 · Cited by 587
Toll-like receptor signaling in neural plasticity and disease
Okun, E., Griffioen, K. J., & Mattson, M. P. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2011.02.005 · Cited by 510
Therapeutic Targeting of Toll-Like Receptors for Infectious and Inflammatory Diseases and Cancer
O’Neill, L. A. J., Bryant, C. E., & Doyle, S. L. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001073 · Cited by 427
The Yin and Yang of Toll-like receptors in cancer
Pradere, J.-P., Dapito, D. H., & Schwabe, R. F. (2014) · Oncogene · doi:10.1038/onc.2013.302 · Cited by 331
Metadata
- Authors
- Schön, M. P., & Schön, M.
- Venue
- Oncogene
- Published
- 2008-01-07
- Volume
- 27
- Issue
- 2
- Pages
- 190-199
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2010333332
- Cited by
- 296
- References
- 83
- FWCI
- 7.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.